A recent study examining the immune microenvironment in multiple myeloma, following treatment with CD38-targeted immunotherapy and proteasome/IMiD combination, showed that the expansion of monocytes, NK-cell activation, and depletion of T cells were associated with sustained MRD negativity (13). This evidence concerns the gene CD38 and plasma cell myeloma.